Mabswitch, Inc.
Publicly observedVan Nuys, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Van Nuys | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Mabswitch, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MZ15MPUFBHN9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors
USD 399,998.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant10 Sept 2026Publicly observed
NIH SBIR/STTR award: Affinity-tunable Antibody Drug Conjugate (ADC) against High-Grade Serous Ovarian Cancer
USD 399,992.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.